Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Summary

The purpose of this phase II trial is to evaluate the safety and efficacy of standard of care chemotherapy followed by stereotactic body radiotherapy (SBRT) with concurrent and adjuvant FKA inhibitor Defactinib (experimental arm) or standard of care therapy followed by SBRT (control arm) in patients with advanced pancreatic cancer.

General Information

NCT#: NCT04331041
Study ID: 202106061
Trial Phase: Phase II

Trial Sponsor: Washington University School of Medicine
Therapies Used in This Trial: Defactinib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search